Afatinib for Advanced Cancers Carrying an EGFR, HER2, or HER3 Mutation: An Open-Label, Phase II, Belgian Precision Study

JCO Precision Oncology · Published 2026-07-01 · DOI 10.1200/po-25-01198

Authors (12)

Lore Decoster, Philippe Aftimos, Sylvie Rottey, Hans Prenen, Joelle Collignon, Jeroen Mebis, Jean Luc Canon, Vanessa Fastenaekels, Nadia Cappoen, Anna Kondrat, Sofie Joris, Jacques De Grève

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Decoster, L., Aftimos, P., Rottey, S., et al. (2026). Afatinib for Advanced Cancers Carrying an EGFR, HER2, or HER3 Mutation: An Open-Label, Phase II, Belgian Precision Study. JCO Precision Oncology. https://doi.org/10.1200/po-25-01198

Related articles